Angiotensin (1-7) peptide replacement therapy with plasma transfusion in COVID-19.

ABSTRACT:

Aim

To determine whether convalescent angiotensin (1-7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection.

Study design

Case series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment. Peptide plasma: Plasma with angiotensin (1-7) content 8-10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days.

Results

In our COVID-19 case

SUBMITTER: Onal H 

PROVIDER: S-EPMC8917875 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature